The Newest Tool in the Bag: A Pharmacist’s Guide to Third-Line cGVHD Therapy

Clinical pharmacy specialists Brooke Adams, PharmD, BCOP, of Orlando Health, and Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, of The University of Kansas Health System, examine axatilimab (Niktimvo; Incyte) as a third-line therapeutic option for chronic graft-versus-host disease (cGVHD), comparing its CSF1R-targeted mechanism to existing approved agents and evaluating efficacy data alongside real-world clinical experience.